Favorable outcome of HIV-associated Burkitt lymphoma in the modern combined antiretroviral therapy era

Eur J Cancer. 2020 Oct:138:189-192. doi: 10.1016/j.ejca.2020.07.033. Epub 2020 Sep 4.
No abstract available

Publication types

  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-Retroviral Agents / adverse effects
  • Anti-Retroviral Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Burkitt Lymphoma / diagnosis
  • Burkitt Lymphoma / drug therapy*
  • Burkitt Lymphoma / mortality
  • Burkitt Lymphoma / virology
  • Drug Therapy, Combination
  • Female
  • France
  • HIV Infections / diagnosis
  • HIV Infections / drug therapy*
  • HIV Infections / mortality
  • HIV Infections / virology
  • Humans
  • Lymphoma, AIDS-Related / diagnosis
  • Lymphoma, AIDS-Related / drug therapy*
  • Lymphoma, AIDS-Related / mortality
  • Lymphoma, AIDS-Related / virology
  • Male
  • Middle Aged
  • Progression-Free Survival
  • Prospective Studies
  • Time Factors

Substances

  • Anti-Retroviral Agents